Pioneering a first-in-class drug-targeting approach that leverages hormone analogues to deliver small-molecule neuroplasticity modulators directly to the brain's appetite control centersFinancing ...

COPENHAGEN/LONDON, May 7 (Reuters) - Obesity drugmaker Novo Nordisk (NOVOb.CO), opens new tab said on Wednesday it would drop gender representation requirements for senior leadership positions in ...

Danish pharmaceutical company Novo Nordisk increased its first-quarter revenue and profit in 2025 compared to the same period ...

BAGSVAERD, Denmark (AP) — BAGSVAERD, Denmark (AP) — Novo Nordisk A/S (NVO) on Wednesday reported first-quarter earnings of $4.09 billion. The Bagsvaerd, Denmark-based company said it had ...

COPENHAGEN/LONDON (Reuters) - Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for senior leadership positions in its U.S. business following ...

COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month ...

Healthcare & Pharmaceuticalscategory Novo Nordisk shares up on hopes for US Wegovy recovery 11:21 AM UTC · Updated ago Healthcare & Pharmaceuticalscategory Novo Nordisk's CFO sceptical Trump ...

a small-molecule drug designed to boost calorie expenditure in the body as a way to combat obesity. As part of the deal, Novo Nordisk has entered into a three-year collaboration with Embark ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Ousia Pharma logo Omega Funds Logo . Pioneering a first-in-class drug-targeting approach that leverages hormone analogues to deliver small-molecule neuroplas ...